Browse Articles
Discover research articles across all indexed journals
Single-cell analysis and functional profiling to reveal Galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma.
245 Background: Histological transformation of follicular lymphoma (tFL) represents an aggressive subtype characterized by a complex and immunosuppressive tumor immune microenvironment (TIME). Therefore, it is urgent to investigate the characteristics of TIME and develop more effective immunotherapy strategies for tFL patients. Methods: Using single-cell RNA sequencing, a high-resolution landscape of the entire TIME ecosystem of follicular lymphoma (FL) and tFL patients is depicted. Findings were validated by multiplex immunofluorescence (mIF) staining, in vitro assays, and a mouse model. Results: Compared to FL patients, tFL patients exhibited a higher proportion of exhausted CD8+T cells expressing checkpoint receptors such as LAG3, CTLA4, PD-1, and HAVCR2. Notably, Galectin-3 expression was acquired by tumor cells after transformation, leading to enhanced Galectin-3–LAG3 interactions with CD8⁺ T cells, as confirmed by mIF staining. In co-culture experiments, Galectin-3-overexpressing tumor cells impaired CD8⁺ T cell proliferation and cytotoxicity, inducing an exhausted phenotype. Treatment with the Galectin-3 inhibitor GB1107 rescued T cell function. Similar T cell dysfunction and GB1107 response were observed in Galectin-3-overexpressing mouse xenograft model. Additionally, we identified an accumulation of MDSC-like monocytes and M2-like macrophages in tFL patients, further contributing to immune suppression. Conclusions: Galectin-3 drives T cell exhaustion and reshapes the immune microenvironment in tFL patients, promoting immune evasion and disease progression. Targeting Galectin-3 may represent a promising immunotherapeutic strategy for tFL patients.
Sulfonyl-γ-AAs as Turn Templates Inducing β-Sheet Conformation in Macrocyclic Peptides
Correction to “Biomimetic Design of Artificial Hybrid Nanocells for Boosted Vascular Regeneration in Ischemic Tissues”
Differential ErbB receptor dimerization modulates the ability of EGF receptor ligands to regulate metabolic flux
First-line maintenance olaparib in a low–body mass index Asian population with advanced ovarian cancer: Real-world outcomes from a Vietnamese cohort.
218 Background: Patients enrolled in pivotal poly(ADP-ribose) polymerase (PARP) inhibitor trials predominantly represent Western populations with relatively higher body mass index (BMI), whereas Asian patients typically present with substantially lower BMI. Whether this difference influences the effectiveness and tolerability of fixed-dose olaparib remains uncertain. We evaluated real-world outcomes of first-line maintenance olaparib in a Vietnamese cohort characterized by predominantly low BMI. Methods: This retrospective cohort study included patients with FIGO stage III–IV ovarian cancer treated at Vietnam National Cancer Hospital who received first-line maintenance olaparib with or without bevacizumab between 2021 and 2025. BMI at treatment initiation was analyzed as a continuous variable and categorized using Asian BMI criteria (< 23 vs ≥23 kg/m²). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods, and toxicities were graded according to CTCAE v5.0. Results: Thirty-two patients were included. The mean age was 54.9 ± 10.0 years (range 39–74). Median BMI was 22.1 kg/m², and 68.8% of patients had BMI < 23 kg/m², and 62.5% had BRCA1/2 mutations. At a median follow-up of 24 months, 12- and 24-month PFS rates were 85.2% and 78.7%, respectively, while corresponding OS rates were 95.7% and 90.0%. Patients with BRCA mutations demonstrated significantly superior 24-month PFS compared with HRD-positive, BRCA–wild-type patients (91.7% vs. 59.5%, p = 0.008). Treatment-related toxicities were manageable and did not increase among lower-BMI patients. Dose reduction and discontinuation occurred in 25.0% and 3.1%, respectively. Grade ≥3 anemia occurred in 15.6%, with similar rates between BMI < 23 and ≥23 groups (13.6% vs. 20.0%). Conclusions: In this real-world LMIC cohort with predominantly low BMI, first-line maintenance olaparib demonstrated effectiveness and safety comparable to pivotal trials conducted in higher-BMI Western populations.
Synthesis and Properties of Stable Oxo-Bridged Dinuclear Pr <sup>IV</sup> Complexes
Inversed Cation Size Effects on Methanol Formations From CO <sub>2</sub> Electroreduction by Immobilized Cobalt Phthalocyanine
ABSTRACT The electrocatalytic reduction of CO 2 to methanol offers a compelling pathway for sustainable fuel synthesis, wherein cations in the electric double layer (EDL) exert a substantial influence on catalytic performance. Although cation modulation of CO 2 ‐to‐CO conversion has been extensively documented, its influence on downstream reduction pathways toward CH 3 OH has received comparatively little attention. Using multiscale simulation, we establish that methanol synthesis over immobilized cobalt phthalocyanine (CoPc) is kinetically governed by the final proton transfer (*CH 2 OH + H 2 O → * + CH 3 OH + OH − ). The EDL environment substantially accelerates this rate‐determining step (RDS). Moreover, the activity exhibits a clear dependence on cation radius, following the trend Li + > Na + > K + > Cs + , with smaller cations systematically lowering the proton transfer barrier. This trend stems from the enhanced accessibility of smaller cations to the transition state, where Li + achieves tighter coordination than Cs + , conferring greater electrostatic stabilization and a correspondingly reduced barrier. Conversely, smaller cations attenuate the hydrogen‐bond network surrounding OH − , potentially impeding OH − transfer from the catalyst surface to the bulk electrolyte. These multifaceted cation effects underscore the complex interplay between kinetic promotion and mass transfer limitations in electrocatalytic systems.
Neural Population Dynamics in Primate Multisensory Cortical Areas during Heading Discrimination
Cortical areas involved in self-motion perception process cues from multiple sensory modalities, primarily visual and vestibular, alongside choice-related activity. Neurons in these regions often respond to combinations of these factors—demonstrating a high degree of mixed selectivity. Moreover, self-motion is inherently dynamic, with each cue—visual and vestibular—comprising a mix of distinct motion signals, such as velocity and acceleration, that evolve over time. Here, we developed a time-varying targeted dimensionality reduction method to expose these dynamic motion and choice-related signals in neuronal populations. We applied this approach to recordings from the ventral intraparietal cortex (VIP), dorsal medial superior temporal cortex (MSTd), and parietoinsular vestibular cortex (PIVC), in six male rhesus macaques, performing a task of heading discrimination. Distinct configurations of dynamic signals were seen in the population activity across the different cortical areas. VIP exhibited all components—namely, velocity and acceleration, for visual and vestibular cues, along with strong choice-related signals that rose early and remained elevated throughout the stimulus period, well before the choice was reported. In contrast, MSTd and PIVC had weaker and later choice-related activity. MSTd primarily exhibited visual signals (velocity more than acceleration) with weak vestibular signals. PIVC predominantly exhibited vestibular signals (velocity and acceleration), yet visual signals were nonetheless present. The distinct configurations of time-varying parameters across VIP, MSTd, and PIVC likely reflect different functional specializations in heading discrimination.
A novel sorting method uncovers metabolic heterogeneity between mononucleated and binucleated tetraploid hepatocytes
Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.
211 Background: Currently, the established first-line therapy for patients with recurrent or metastatic CC is the platinum-paclitaxel plus bevacizumab, yet chemotherapy-associated toxicity remains a concern. Although the addition of immune checkpoint inhibitors (ICIs) to chemotherapy improves survival, it adds cumulative toxicities and limited tolerability. This phase II trial evaluated the efficacy and safety of a chemotherapy-free regimen—penpulimab (anti-PD-1) plus anlotinib (multi-target TKI)—as first-line therapy in patients with persistent, recurrent, or metastatic CC. Methods: This multicenter, single-arm, phase II trial enrolled women (aged 18-75 years, ECOG PS 0-1) with histologically confirmed persistent, recurrent, or metastatic cervical cancer who had progressed after ≥1 platinum-based regimen and were ineligible for curative local therapy. Prior immunotherapy or antiangiogenic therapy was excluded. Treatment consisted of penpulimab (200 mg IV, day 1) plus anlotinib (12 mg orally, days 1-14) in 21-day cycles until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Results: From April 2022 to December 2023, twenty-five patients were enrolled (median age 54 years; 52% stage III at diagnosis; 72% PD-L1 CPS ≥1). With a median follow-up of 19.6 months, ORR was 56% (95% confidence interval [CI], 35-76), including 5 complete and 9 partial responses; DCR was 88% (95% CI, 69-98). Median PFS was 14.8 months (95% CI, 4.8–not estimated [NE]); median OS was 25.4 months (20.1-NE). The 12-month OS rate was 88.0% (95% CI, 67.3–96.0). All patients (100%) experienced at least one treatment-related adverse event (TRAE) of any grade. Grade ≥3 TRAEs occurred in 14 patients (56%), with hypertension (12%) being the most common. No treatment-related deaths occurred, and quality of life remained stable throughout the treatment period. Conclusions: Penpulimab plus anlotinib, as a first-line chemotherapy-free regimen, demonstrated promising clinical activity and a manageable safety profile in patients with persistent, recurrent, or metastatic cervical cancer, supporting its further development as a novel treatment option. Clinical trial information: ChiCTR2100053109.
Air Instability-Induced Mechanical Degradation Plaguing Cyclability of Polycrystalline Nickel-Rich Layered Cathode
Presynaptic Vesicles Supply Membrane for Axonal Bouton Enlargement during Long Term Potentiation
Long-term potentiation (LTP) induces presynaptic bouton enlargement and a reduction in the number of synaptic vesicles. To understand the relationship between these events, we performed 3D analysis of serial section electron micrographs in hippocampal area CA1 from male rats, 2 h after LTP induction. We observed a high vesicle packing density in control boutons, contrasting with a lower density in most LTP boutons. Notably, the summed membrane area of the vesicles lost in low-density LTP boutons is comparable to the surface membrane required for the observed bouton enlargement when compared with high-density control boutons. These novel findings suggest that presynaptic vesicle density provides a new structural indicator of LTP that supports a local mechanism of bouton enlargement.
Crystallization Pathway Optimization and High‐Index Facet Stabilization for Perovskite Photovoltaics
ABSTRACT Perovskite solar cells (PSCs) face a critical challenge in balancing high power conversion efficiency (PCE) with operational stability, largely governed by the crystallization kinetics and facet configuration of perovskite films. Here, we report a kinetically segmented crystallization strategy mediated by a conformationally preorganized macromolecular regulator, cellulose 2,4,6‐trichlorophenylcarbamate (3Cl‐NC). Through multidentate coordination, 3Cl‐NC establishes localized precursor‐rich microenvironments that promote heterogeneous nucleation. During thermal annealing, this association transitions into a thermally activated dynamic coordination state that retards long‐range precursor transport while maintaining local availability for controlled crystal growth. This segmented regulation suppresses metastable δ‐phase accumulation and facilitates photoactive α‐phase formation. Furthermore, 3Cl‐NC thermodynamically stabilizes the high‐Miller‐index (210) orientation, establishing a synergistic architecture that intrinsically enhances lattice structural stability. Consequently, the resulting perovskite films exhibit higher phase purity, relieved residual stress, and suppressed ion migration, enabling devices to achieve a champion PCE of 26.59% (certified 26.29%) with improved long‐term stability.
Ginkgolide A enhances cardiomyocyte differentiation from pluripotent stem cells by targeting cytochrome c to attenuate intrinsic apoptosis
Efficacy of prophylactic dexamethasone in preventing opioid-induced nausea and vomiting in cancer patients: A randomized controlled trial.
313 Background: Opioid initiation for cancer pain is frequently complicated by nausea and vomiting, impairing adherence and delaying dose optimisation. Evidence supporting routine prophylactic antiemetic use during oral morphine initiation remains limited. We evaluated whether a single pre-emptive dose of dexamethasone reduces early opioid-induced nausea and vomiting (OINV). Methods: In this single-centre, open-label, randomized controlled trial , 150 adult cancer patients initiating oral morphine were randomized 1:1 to receive oral dexamethasone 8 mg administered 6 hours prior to morphine or standard care without prophylaxis. The primary endpoint was nausea severity assessed using a Numerical Rating Scale (NRS 0–10). Secondary endpoints included vomiting frequency and rescue antiemetic use assessed on Days 1, 3, and 5. Analyses were conducted on an intention-to-treat basis. Results: A total of 150 patients were randomized (dexamethasone n=74; control n=76). On Day 1, mean nausea scores were significantly lower in the dexamethasone group compared with control (1.86 vs 2.93; mean difference −1.07; p=0.01). The difference remained significant on Day 3 (1.45 vs 2.59; mean difference −1.14; p=0.02) but was not significant by Day 5 (p=0.18). Mean vomiting episodes were reduced on Day 1 (0.45 vs 1.29; mean difference −0.84; p=0.01). Change-from-baseline analysis demonstrated greater reduction in nausea at Day 3 (−0.93 ± 1.22 vs −0.34 ± 1.16; p=0.03) and vomiting frequency (−0.72 ± 1.25 vs −0.04 ± 0.65; p=0.01) in the dexamethasone arm. Differences in vomiting frequency at later time points were not statistically significant. No steroid-related serious adverse events were reported. Conclusions: In this open-label randomized trial, a single prophylactic dose of dexamethasone was associated with significant reduction in early opioid-induced nausea and vomiting during morphine initiation without additional toxicity. Prophylactic dexamethasone may represent a simple and cost-effective strategy to improve opioid tolerability in oncology practice, particularly in resource-limited settings. Clinical trial information: CTRI/2026/02/104005 . Clinical outcomes during opioid initiation. Outcome Dexamethasone (n=74) Control (n=76) Mean Difference p value Nausea severity (NRS 0–10) Day 1 1.86 2.93 −1.07 0.01 Day 3 1.45 2.59 −1.14 0.02 Day 5 1.11 1.53 −0.42 0.18 Vomiting episodes (mean/day) Day 1 0.45 1.29 −0.84 0.01 Day 3 0.41 0.57 −0.16 0.31 Day 5 0.29 0.35 −0.06 0.53 Change from baseline (Day 3 vs Day 1) Nausea severity −0.93 ± 1.22 −0.34 ± 1.16 — 0.03 Vomiting frequency −0.72 ± 1.25 −0.04 ± 0.65 — 0.01
Polymorphic Imidoylamidinato Platinum(II) Complex That Exhibits Inverse Symmetry Breaking Induced by Both Pressure and Temperature
Lifetime and acute risk of suicidality by profiles of early life adversity: an observational cohort study in a high-risk population
Abstract Early life adversity in the form of child maltreatment (CM) is a transdiagnostic risk factor for suicidal ideation and behavior (SIB), yet its heterogeneity and relevance for lifetime versus acute SIB and psychotherapy outcomes remain unclear. In an observational cohort of 240 high-risk adults with borderline personality disorder (42.5%) or persistent depressive disorder (57.5%), lifetime and acute SIB were assessed using the Columbia–Suicide Severity Rating Scale. CM profiles were derived using a data-driven clustering approach based on the Childhood Trauma Questionnaire. Associations between CM profiles, SIB, and symptom change during inpatient cognitive behavioral analysis system of psychotherapy (CBASP) or dialectical behavior therapy (DBT) were examined. Seven distinct CM profiles were identified. A profile characterized by physical and emotional abuse and emotional neglect was associated with elevated lifetime risk for active suicidal ideation with plan and intent and for potentially lethal suicide attempts, compared with minimal CM. CM profiles were not associated with acute SIB or their reduction during inpatient psychotherapy, although differential depressive symptom change by CM profile was observed following CBASP but not DBT. These findings suggest that CM profiling may inform lifetime SIB risk assessment and require replication in larger samples.
Ion‐Selective Transport via Nanoconfined Differential Interfacial Friction in a Dielectric‐Engineered Covalent Organic Framework With Sectionalized Chemical Environments
ABSTRACT Developing solid‐state electrolytes (SSEs) that concurrently deliver high ionic conductivity, excellent ion selectivity, and robust electrochemical/thermal stability remains a central challenge for safe, high‐energy‐density solid‐state batteries (SSBs). Here, an all‐solid‐state covalent organic framework electrolyte with sectionalized chemical environments (SCE‐COF) is reported, constructed via nanoconfined copolymerization of a highly dielectric monomer within COF nanochannels. The resulting architecture affords a nano‐confined molecular interface that integrates electron‐rich polar short chains that form abundant Li + hopping sites with electron‐deficient pore‐wall regions that immobilize anions through specific hydrogen‐bonding interactions, thereby enabling efficient and differential ion transport decoupled from strongly bonded solvation cage and polymer segmental motion. Benefiting from these synergistic effects, SCE‐COF achieves ionic conductivity of 1.05 × 10 −3 S cm −1 at 30°C, a high Li + transference number of 0.73 and a wide electrochemical window (4.87 V vs Li + /Li). Finally, all‐solid‐state full cells employing SCE‐COF deliver a high specific energy density of 442.0 Wh kg −1 under a controlled lithium source at ambient temperature.
Structural basis for selective thymidine binding by the Borrelia burgdorferi substrate-binding protein BmpA
Multi-omics profiling of tumor DNA, mRNA, and plasma ctDNA in advanced lung cancer.
287 Background: The extensive landscape of therapeutic biomarkers in lung cancer has catalyzed the evolution of comprehensive genomic profiling (CGP). In this study, we evaluated the technical performance and clinical utility of a multi-omic approach, integrating DNA and mRNA sequencing for tumor profiling, combined with ctDNA analysis for real-time monitoring. Methods: FFPE samples were collected from 180 patients with advanced lung cancer. Genomic DNA was sequenced using a 504-gene panel with high-density probes (K-4Care, Gene Solutions) to identify actionable biomarkers. Whole mRNA sequencing was performed to detect fusions and predict tissue of origin using the OriCUP machine learning model. For longitudinal ctDNA monitoring, serial plasma samples from 39 patients were analyzed using a combined tumor-informed and tumor-agnostic approach. ctDNA-based molecular response results were subsequently correlated with progression-free survival (PFS). Results: Targeted FFPE DNA sequencing identified actionable mutations in 62.7% (113/180) of the samples. The high-density probe configuration significantly enhanced the sensitivity to detect and quantify copy number variations (CNVs), specifically for MET , EGFR , and MYCN amplifications. Notably, this optimized design enabled the robust detection of MTAP-CDKN2A homozygous deletions, an emerging therapeutic target, in 13.3% (24/180) of cases. For fusion detection, mRNA sequencing showed 20% higher sensitivity compared to DNA sequencing in reference samples. However, with 35% of clinical FFPE samples showing poor RNA quality, combined DNA and mRNA sequencing was critical to maximize fusion detection. For tissue of origin, the OriCUP model predicted lung origin with 88.2% accuracy. In the longitudinal cohort of 39 patients, tumor-agnostic plasma profiling detected resistance mutations in 15.4% (6/39) of cases. Molecular responders, defined by a > 50% reduction in ctDNA level from baseline, demonstrated significantly longer PFS compared to molecular non-responders (HR = 9.53, p < 0.0001; 12-month PFS: 95.5% vs. 33.6%). Conclusions: Integrating genomic with transcriptomic profiling provided a more comprehensive molecular landscape than DNA-only CGP alone. The incorporation of ctDNA analysis further helped identify resistance mutations and evaluate treatment response.